Security Snapshot

Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) Institutional Ownership

CUSIP: 19249H103

13F Institutional Holders and Ownership History from Q4 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

125

Shares (Excl. Options)

51,225,957

Price

$1.42

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CHRS on Nasdaq
Shares outstanding
154,721,181
Price per share
$1.71
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
51,225,957
Total reported value
$72,710,836
% of total 13F portfolios
0%
Share change
-1,270,328
Value change
-$2,068,581
Number of holders
125
Price from insider filings
$1.71
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CHRS - Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 19249H103.
  • 125 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 125 to 85 between Q4 2025 and Q1 2026.
  • Reported value moved from $72,710,836 to $48,387,672.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 125 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 19249H103?
CUSIP 19249H103 identifies CHRS - Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Timothy G. Youngquist 2020 Irrevocable Trust 8.3% $21,872,268 12,790,800 Timothy G. Youngquist 2020 Irrevocable Trust 05 Feb 2026
Bering Partners II, L.P. 6.5% $12,468,441 7,602,708 Evgeny Zaytsev ("Zaytsev") 05 Sep 2025
BlackRock, Inc. 4.9% -24% $12,400,705 -$473,972 7,337,261 -3.7% BlackRock, Inc. 31 Mar 2026
SATTERFIELD THOMAS A JR 4.6% -12% $11,711,700 +$1,555,621 6,930,000 +15% Thomas A. Satterfield, Jr. 31 Mar 2026
Rubric Capital Management LP 4.6% $5,258,754 5,258,754 Rubric Capital Management LP 31 Dec 2024

As of 31 Dec 2025, 125 institutional investors reported holding 51,225,957 shares of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS). This represents 33% of the company’s total 154,721,181 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) together control 30% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6.8% 10,562,709 +0.98% 0% $14,999,046
VANGUARD GROUP INC 6.5% 10,028,893 -2.8% 0% $14,241,029
Kohlberg Kravis Roberts & Co. L.P. 2% 3,036,076 0% 0.07% $4,246,630
GEODE CAPITAL MANAGEMENT, LLC 1.8% 2,745,246 +0.15% 0% $3,898,942
TANG CAPITAL MANAGEMENT LLC 1.8% 2,724,509 -47% 0.19% $3,868,803
STATE STREET CORP 1.4% 2,223,396 +0% 0% $3,157,222
CM Management, LLC 1.4% 2,100,000 0% 2.5% $2,982,000
C WorldWide Group Holding A/S 1.2% 1,928,464 0% 0.05% $2,738,000
PANAGORA ASSET MANAGEMENT INC 1% 1,620,271 +18% 0.01% $2,300,785
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.6% 935,239 -5.8% 0% $1,328,039
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.58% 899,999 0% 0% $1,278,000
AQR CAPITAL MANAGEMENT LLC 0.57% 885,720 -1.9% 0% $1,257,723
Hudson Bay Capital Management LP 0.54% 835,000 +3.1% 0.01% $1,185,700
NORTHERN TRUST CORP 0.51% 793,313 -6.7% 0% $1,126,504
MILLENNIUM MANAGEMENT LLC 0.43% 660,451 0% $937,840
UBS Group AG 0.39% 610,803 -23% 0% $867,341
JANE STREET GROUP, LLC 0.39% 603,510 +187% 0% $856,984
TWO SIGMA INVESTMENTS, LP 0.33% 503,875 +1311% 0% $715,502
GSA CAPITAL PARTNERS LLP 0.31% 477,481 0.06% $678,000
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.29% 441,000 +73% 0.01% $626,220
Jefferies Financial Group Inc. 0.26% 395,190 +21% 0% $561,170
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.25% 382,241 -5.4% 0% $542,782
Invesco Ltd. 0.25% 380,033 +46% 0% $539,647
BARCLAYS PLC 0.22% 345,573 +18% 0% $490,713
STRS OHIO 0.21% 324,000 0% 0% $460,080

Institutional Holders of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 28,631,104 $48,387,672 +$1,427,693 $1.69 85
2025 Q4 51,225,957 $72,710,836 -$2,068,581 $1.42 125
2025 Q3 51,511,878 $84,436,218 -$2,969,339 $1.64 110
2025 Q2 55,358,578 $40,439,575 -$4,928,963 $0.73 109
2025 Q1 62,082,313 $50,064,190 -$6,457,989 $0.81 114
2024 Q4 65,594,814 $90,489,403 -$12,493,801 $1.38 121
2024 Q3 76,943,748 $79,924,458 -$11,982,900 $1.04 127
2024 Q2 82,580,425 $142,867,620 -$603,275 $1.73 132
2024 Q1 82,494,208 $197,162,680 -$5,908,937 $2.39 134
2023 Q4 81,477,441 $271,309,409 -$37,399,801 $3.33 153
2023 Q3 92,968,604 $347,619,918 +$14,526,156 $3.74 168
2023 Q2 86,685,207 $370,290,994 +$30,644,927 $4.27 159
2023 Q1 78,433,333 $536,456,842 -$2,030,485 $6.84 163
2022 Q4 78,672,183 $622,985,097 +$2,380,758 $7.92 160
2022 Q3 77,664,501 $746,258,214 -$14,908,210 $9.61 168
2022 Q2 78,904,235 $571,951,639 +$12,362,063 $7.24 171
2022 Q1 75,936,074 $979,679,788 -$19,093,537 $12.91 172
2021 Q4 76,732,060 $1,226,275,602 +$9,148,757 $15.96 190
2021 Q3 76,118,247 $1,224,124,361 -$23,896,897 $16.07 182
2021 Q2 77,861,825 $1,077,307,964 -$38,365,571 $13.83 184
2021 Q1 80,296,427 $1,174,206,082 -$126,382,516 $14.61 201
2020 Q4 86,846,381 $1,509,532,138 +$7,068,870 $17.38 191
2020 Q3 87,967,283 $1,615,322,964 -$17,575,985 $18.34 200
2020 Q2 86,666,598 $1,547,355,972 +$228,840,811 $17.86 187
2020 Q1 74,669,838 $1,211,513,949 +$27,802,781 $16.22 185
2019 Q4 72,711,303 $1,309,075,614 +$50,544,709 $18.00 184
2019 Q3 69,362,054 $1,405,299,052 +$54,882,205 $20.26 165
2019 Q2 66,788,293 $1,473,155,747 +$29,409,971 $22.10 145
2019 Q1 68,742,401 $937,662,508 +$43,941,561 $13.64 114
2018 Q4 65,705,169 $594,602,586 -$13,874,058 $9.05 107
2018 Q3 63,584,248 $1,049,141,419 +$28,536,991 $16.50 106
2018 Q2 61,953,349 $867,373,516 +$96,221,276 $14.00 112
2018 Q1 55,290,055 $610,960,009 +$32,866,184 $11.05 102
2017 Q4 49,467,518 $435,305,054 +$17,238,403 $8.80 92
2017 Q3 46,927,893 $626,702,945 +$87,202,617 $13.35 90
2017 Q2 40,123,971 $575,784,532 +$26,148,562 $14.35 105
2017 Q1 37,510,462 $793,275,948 +$210,973,219 $21.15 109
2016 Q4 29,921,898 $842,300,808 +$50,764,547 $28.15 122
2016 Q3 28,142,776 $753,581,042 +$78,368,033 $26.78 116
2016 Q2 25,321,897 $427,677,064 +$112,113,002 $16.89 86
2016 Q1 18,234,639 $387,025,000 +$29,114,088 $21.23 74
2015 Q4 16,721,851 $383,952,785 +$8,941,726 $22.96 76
2015 Q3 16,091,708 $322,474,715 +$17,279,435 $20.04 76
2015 Q2 15,045,116 $433,747,071 +$223,061,016 $28.90 73
2015 Q1 7,268,421 $221,671,439 -$28,139,852 $30.58 49
2014 Q4 9,850,113 $157,559,817 +$157,548,817 $16.32 37
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .